SEC Form SC 13G/A filed by Erasca Inc. (Amendment)

$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ERAS alert in real time by email
SC 13G/A 1 d743522dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

 

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

 

Erasca, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

29479A108

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 29479A108    Schedule 13G    Page 1 of 8

 

 1   

Names of Reporting Persons

 

City Hill, LLC

 2   

Check the Appropriate Box if a Member of a Group

(a)  ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person With     5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

12,899,360

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

12,899,360

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

12,899,360

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

8.5%

12   

Type of Reporting Person

 

OO


CUSIP No. 29479A108    Schedule 13G    Page 2 of 8

 

 1   

Names of Reporting Persons

 

Jonathan E. Lim

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Canada

Number of Shares Beneficially  Owned by Each Reporting Person With     5   

Sole Voting Power

 

770,500

    6   

Shared Voting Power

 

32,355,576

    7   

Sole Dispositive Power

 

770,500

    8   

Shared Dispositive Power

 

32,355,576

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

33,126,076

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

21.8%

12   

Type of Reporting Person

 

IN


CUSIP No. 29479A108    Schedule 13G    Page 3 of 8

 

 1   

Names of Reporting Persons

 

Conyee T. Lim

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

United States

Number of Shares Beneficially  Owned by Each Reporting Person With     5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

19,456,216

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

19,456,216

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

19,456,216

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

12.9%

12   

Type of Reporting Person

 

IN


CUSIP No. 29479A108    Schedule 13G    Page 4 of 8

 

ITEM 1.

(a)  Name of Issuer:

Erasca, Inc. (the “Issuer”).

 

  (b)

Address of Issuer’s Principal Executive Offices:

3115 Merryfield Row, Suite 300, San Diego, CA 92121

 

ITEM 2.

(a)  Name of Person Filing:

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

City Hill, LLC

Jonathan E. Lim

Conyee T. Lim

 

  (b)

Address or Principal Business Office:

The principal business address of the Reporting Persons is c/o Erasca, Inc., 3115 Merryfield Row, Suite 300, San Diego, CA 92121.

 

  (c)

Citizenship of each Reporting Person is:

City Hill, LLC is organized under the laws of the State of Delaware. Jonathan E. Lim is a citizen of Canada and Conyee T. Lim is a citizen of the United States.

 

  (d)

Title of Class of Securities:

Common stock, $0.0001 par value per share (“Common Stock”).

 

  (e)

CUSIP Number:

29479A108

 

ITEM 3.

Not applicable.


CUSIP No. 29479A108    Schedule 13G    Page 5 of 8

 

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Common Stock as of December 31, 2023, based upon 151,087,038 shares of Common Stock outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

 

Reporting Person   

Amount

beneficially 

owned

    

Percent

of class:

   

Sole

power

to vote

or to

direct

the vote:

    

Shared

power to

vote or to

direct the

vote:

    

Sole

power to

dispose or

to direct

the

disposition

of:

    

Shared

power to

dispose or

to direct

the

disposition

of:

 

City Hill, LLC

     12,899,360        8.5     0        12,899,360        0        12,899,360  

Jonathan E. Lim

     33,126,076        21.8     770,500        32,355,576        770,500        32,355,576  

Conyee T. Lim

     19,456,216        12.9     0        19,456,216        0        19,456,216  

City Hill, LLC is the record holder of 12,899,360 shares of Common Stock. Jonathan E. Lim is the Managing Partner of City Hill, LLC and as a result may be deemed to share beneficial ownership of the shares of Common Stock held of record by City Hill, LLC. Jonathan E. Lim may be deemed to beneficially own 770,500 shares of Common Stock underlying stock options exercisable on or within 60 days of December 31, 2023.

In addition, Jonathan E. Lim and Conyee T. Lim serve as co-trustees of a family trust that is the record holder of 19,456,216 shares of Common Stock. As a result, each of Jonathan E. Lim and Conyee T. Lim may be deemed to share beneficial ownership of the shares of Common Stock held of record by such trust.

 

ITEM 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.


CUSIP No. 29479A108    Schedule 13G    Page 6 of 8

 

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

 

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

 

ITEM 10.

Certification.

Not applicable.


CUSIP No. 29479A108    Schedule 13G    Page 7 of 8

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2024

 

City Hill, LLC
By:   /s/ Jonathan E. Lim, M.D.
Name:   Jonathan E. Lim, M.D.
Title:   Managing Partner

 

Jonathan E. Lim
/s/ Jonathan E. Lim, M.D.
Conyee T. Lim
/s/ Conyee T. Lim, M.D.


CUSIP No. 29479A108    Schedule 13G    Page 8 of 8

 

LIST OF EXHIBITS

 

Exhibit No.

  

Description

99    Joint Filing Agreement (previously filed).
Get the next $ERAS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ERAS

DatePrice TargetRatingAnalyst
3/26/2025$5.00Outperform
Raymond James
11/18/2024$6.00Buy
Jefferies
3/11/2024$8.00Overweight
CapitalOne
1/5/2024$11.00 → $6.00Buy → Neutral
BofA Securities
10/11/2023$10.00Buy
H.C. Wainwright
3/30/2023$9.00Buy
Mizuho
2/24/2023$10.00Buy
Goldman
2/3/2023$15.00Equal-Weight → Overweight
Morgan Stanley
More analyst ratings

$ERAS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

    Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025,

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

    Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

    SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ERAS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ERAS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ERAS
SEC Filings

See more

$ERAS
Leadership Updates

Live Leadership Updates

See more
  • Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Financials

Live finance-specific insights

See more
  • Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports First Quarter 2024 Business Updates and Financial Results

    Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more